Epigenetic Mechanisms Underlying the Pathogenesis of Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)

被引：0
|
作者：
Cheng, J. X.
Anastasi, J.
Shen, J. Q.
Watanabe, K.
Grimley, E.
Kleinbrink, E.
Knibbs, R.
Roulston, D.
Vardiman, J. W.
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
[2] Univ Chicago, Chicago, IL 60637 USA
[3] Univ Nevada, Las Vegas, NV 89154 USA
来源：
LABORATORY INVESTIGATION | 2012年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
1382
引用
收藏
页码：329A / 330A
页数：2
相关论文
共 50 条
  • [41] Risk assessment in chronic myelomonocytic leukemia (CMML)
    Germing, U
    Kündgen, A
    Gattermann, N
    LEUKEMIA & LYMPHOMA, 2004, 45 (07) : 1311 - 1318
  • [42] RANDOMIZED PHASE 2 STUDY OF GUADECITABINE IN PATIENTS WITH HMA-NAIVE HIGHER RISK MYELODYSPLASTIC SYNDROMES (MDS) OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
    Savona, M. R.
    Garcia-Manero, G.
    Roboz, G. J.
    Walsh, K. J.
    Kropf, P. L.
    Issa, J. P.
    O'Connell, C. L.
    Tibes, R.
    Yee, K. W. L.
    Stock, W.
    Lunin, S.
    Berdeja, J. G.
    Naim, S.
    Hao, Y.
    Azab, M.
    Kantarjian, H.
    LEUKEMIA RESEARCH, 2017, 55 : S40 - S41
  • [43] An IPSS-R Cutpoint of 3 Stratified Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) Patients (pts) into Two Risk Groups
    Montoro, Julia
    Pomares, Helena
    Merchan, Brayan
    Molero, Antonieta
    Saumell, Silvia
    Alonso, Esther
    Fernandez, Monica
    Gallur, Laura
    Grau, Javier
    Salamero, Olga
    Blanco, Adoracion
    Varela, Anna
    Roldan, Elisa
    Sureda, Anna
    Bosch, Francesc
    Sangerman, Montserrat Arnan
    Valcarcel, David
    BLOOD, 2017, 130
  • [44] CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) PATIENTS WITH LYSOZYME NEPHROPATHY AND CMML RENAL
    Lafargue, Marie-Camille
    Van Huyen, Jean-Paul Duong
    Isnard, Pierre
    Rennke, Helmut
    Essig, Marie
    Carre, Martin
    Mercadal, Lucile
    Farhi, Jonathan
    Bobot, Mickael
    Sakhi, Hamza
    Comont, Thibault
    Golbin, Leonard
    Chemouny, Jonathan
    Cambier, Nathalie
    Laribi, Kamel
    Selamet, Umut
    Riella, Leonardo
    Fain, Olivier
    Ades, Lionel
    Fenaux, Pierre
    Cohen, Camille
    Mekinian, Arsene
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I380 - I381
  • [45] Clinical Outcomes of Oligomonocytic Chronic Myelomonocytic Leukemia (OM-CMML) and Predictive Factors of Evolution of OM-CMML into Overt Chronic Myelomonocytic Leukemia (CMML)
    Roman-Bravo, David
    Arenillas, Leonor
    Asensi, Maria Teresa
    Garcia-Gisbert, Nieves
    Rodriguez-Sevilla, Juan Jose
    Merchan, Brayan
    Avila, Sara Garcia
    Bellosillo, Beatriz
    Fernandez-Rodriguez, Concepcion
    Florensa, Lourdes
    Ferrer, Ana
    Calvo, Xavier
    BLOOD, 2021, 138
  • [46] Development of Oral Azacitidine with Cedazuridine for Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms ( MPN) Including CMML (Chronic Myelomonocytic Leukemia) By Targeting Pharmacokinetic AUC Equivalence Vs Subcutaneous Azacitidine
    Garcia-Manero, Guillermo
    McCloskey, James
    Scott, Bart L.
    Griffiths, Elizabeth A.
    Kiner-Strachan, Bonnie
    Roboz, Gail J.
    Meyer, Janelle
    Chan, Winny
    Mirakhur, Beloo
    Sano, Yuri
    Oganesian, Aram
    Keer, Harold N.
    Savona, Michael R.
    BLOOD, 2023, 142
  • [47] A Phase I/II Study of Venetoclax in Combination with 5Azacytidine in Treatment-Naive and Relapsed/Refractory HighRisk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
    Bazinet, Alexandre
    Jabbour, Elias J.
    Kantarjian, Hagop
    Chien, Kelly S.
    DiNardo, Courtney D.
    Ohanian, Maro
    Daver, Naval
    Kanagal-Shamanna, Rashmi
    Kadia, Tapan M.
    Takahashi, Koichi
    Masarova, Lucia
    Short, Nicholas J.
    Alvarado, Yesid
    Thompson, Philip A.
    Montalban-Bravo, Guillermo
    Yilmaz, Musa
    Ravandi, Farhad
    Kornblau, Steven M.
    Pemmaraju, Naveen
    Schneider, Heather
    Mirabella, Bailey
    Naqvi, Kiran
    Garcia-Manero, Guillermo
    BLOOD, 2021, 138
  • [48] Development of Oral Azacitidine With Cedazuridine for Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) Including Chronic Myelomonocytic Leukemia (CMML) by Targeting Pharmacokinetic AUC Equivalence vs Subcutaneous Azacitidine
    Garcia-Manero, Guillermo
    McCloskey, James
    Scott, Bart L.
    Griffiths, Elizabeth A.
    Kiner-Strachan, Bonnie
    Roboz, Gail J.
    Meyer, Janelle
    Chan, Winny
    Sano, Yuri
    Oganesian, Aram
    Keer, Harold K.
    Savona, Michael R.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S406 - S407
  • [49] Identification of the Involvement of the Tyrosine Kinase C-Ros in the Pathogenesis of Chronic Myelomonocytic Leukemia (CMML)
    Cilloni, Daniela
    Carturan, Sonia
    Bracco, Enrico
    Defilippi, Ilaria
    Maffe, Chiara
    Iacobucci, Ilaria
    Pautasso, Marisa
    Rotolo, Antonia
    Giugliano, Emilia
    Messa, Emanuela
    Martinelli, Giovanni
    Saglio, Giuseppe
    BLOOD, 2008, 112 (11) : 256 - 256
  • [50] Identification of the involvement of the tyrosine kinase c-Ros in the pathogenesis of chronic myelomonocytic leukemia (CMML)
    Carturan, Sonia
    Bracco, Enrico
    Maffe, Chiara
    Iacobucci, Ilaria
    Messa, Francesca
    Arruga, Francesca
    Pradotto, Monica
    Pautasso, Marisa
    Fornaciari, Paolo
    Messa, Emanuela
    Panuzzo, Cristina
    Leone, Marco
    Martinelli, Giovanni
    Baccarani, Michele
    Gaidano, Gianluca
    Saglio, Giuseppe
    Cilloni, Daniela
    CANCER RESEARCH, 2009, 69
12345